Cargando…

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine therapy is the fundamental treatment against this entity, by directly or indirectly modifying estrogen production. Recent advances in novel compounds, such as cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hernando, Cristina, Ortega-Morillo, Belén, Tapia, Marta, Moragón, Santiago, Martínez, María Teresa, Eroles, Pilar, Garrido-Cano, Iris, Adam-Artigues, Anna, Lluch, Ana, Bermejo, Begoña, Cejalvo, Juan Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345926/ https://www.ncbi.nlm.nih.gov/pubmed/34360578 http://dx.doi.org/10.3390/ijms22157812

Ejemplares similares

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2021)

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer
por: Garrido-Cano, Iris, et al.
Publicado: (2020)

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer
por: Adam-Artigues, A., et al.
Publicado: (2021)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
por: Garrido-Cano, Iris, et al.
Publicado: (2023)

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
por: Pattanayak, Birlipta, et al.
Publicado: (2020)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies
por: Garrido‐Cano, Iris, et al.
Publicado: (2022)

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
por: Downton, Teesha, et al.
Publicado: (2022)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Effect of a brain‐penetrant selective estrogen receptor degrader (SERD) on binge drinking in female mice
por: Chen, Hu, et al.
Publicado: (2022)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2023)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

The GBT-SerDes ASIC prototype
por: Moreira, P, et al.
Publicado: (2010)

High speed serdes devices and applications
por: Stauffer, David R, et al.
Publicado: (2008)

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
por: Guo, Shanchun, et al.
Publicado: (2018)

Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
por: Zhang, Changde, et al.
Publicado: (2017)

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
por: Oltra, Sara S., et al.
Publicado: (2020)

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
por: Zhou, Feng, et al.
Publicado: (2023)

Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients
por: Rodrigues, Patricia, et al.
Publicado: (2012)

MicroRNAs as a clue to overcome breast cancer treatment resistance
por: Garrido-Cano, Iris, et al.
Publicado: (2021)

Associations between Aromatase CYP19 rs10046 Polymorphism and Breast Cancer Risk: From a Case-Control to a Meta-Analysis of 20,098 Subjects
por: Pineda, Begoña, et al.
Publicado: (2013)

The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
por: Wang, Yating, et al.
Publicado: (2022)

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
por: Tormo, Eduardo, et al.
Publicado: (2019)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
por: Tamura, Kenji, et al.
Publicado: (2023)

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
por: Tormo, Eduardo, et al.
Publicado: (2017)

Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
por: Gebrekidan, Medhanie Tesfay, et al.
Publicado: (2018)

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2016)

miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker
por: Oltra, Sara S, et al.
Publicado: (2020)

Accurate in vivo tumor detection using plasmonic-enhanced shifted-excitation Raman difference spectroscopy (SERDS)
por: Strobbia, Pietro, et al.
Publicado: (2021)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
por: Fanning, Sean W, et al.
Publicado: (2018)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
por: Pattanayak, Birlipta, et al.
Publicado: (2022)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression Project
por: Belltall, Amparo, et al.
Publicado: (2022)

Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator
por: Martínez, María Teresa, et al.
Publicado: (2019)

Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study
por: Belltall, Amparo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_49kgbj00m82r0sqo3pkgfvehns